The aim of this study is to determine the diagnostic accuracy of antithyroglobulin antibodies in predicting recurrent differentiated thyroid carcinoma. We searched PubMed (1990-2010) and Google Scholar (1990-2010). Citation searches, manual searches and screening of references of f included studies were done. Diagnostic studies that utilized antithyroglobulin antibodies as a predictor of recurrent differentiated thyroid carcinoma. The authors searched citations that correlated with the criteria using a data collection form generated in Review Manager 5 (REVMAN 5). The methodological quality was then assessed using Quality Assessment of Studies of Diagnostic Accuracy (QUADAS). Hierarchical summary receiver operating characteristic (HSROC) mete-analytical tool was used to estimate summary receiver operating characteristic (ROC) curves. Eight studies with 2116 participants with 182 patients with recurrent differentiated thyroid carcinoma were included. Pooled sensitivity and specifically were 63% and 79% respectively. SROC shows an overall are under the curve (AUC) of 0.712. Antithyroglobulin antibody has ability to predict recurrent differentiated thyroid carcinoma.
THYROID NEOPLASMS ; NEOPLASMS ; NEOPLASMS BY SITE ; ENDOCRINE GLAND NEOPLASMS

A 19-year old man presented with acute onset of intractable hypertension with associated dizziness and nausea. Abdominal computed tomography revealed a 7.0cm x 6.27cm x 6.0cm suprarenal mass on the right. The patient was diagnosed to have pheochromocytoma and successfully underwent retroperitoneal laparoscopic adrenalectomy.

Human ; Male ; Young Adult ; Adrenalectomy ; Surgical Procedures, Operative ; Endocrine Surgical Procedures ; Laparoscopy ; Adrenal Gland Neoplasms ; Neoplasms ; Endocrine Gland Neoplasms

Medullary thyroid carcinoma(MTC) is a malignancy of the thyroid C-cells, and it compromises 5-10% of all thyroid cancers. MTC occurs in both sporadic and hereditary types, the latter making up 25% of all MTCs and being compromised of three distinct syndromesmultiple endocrine neoplasia type IIa(MEN IIa), multiple endocrine neoplasia type IIb(MEN IIb), and familial medullary thyroid carcinoma(FMTC). To date, screening for MTC subtype is important for proper diagnosis and treatment. Recently, the authors experienced a case of FMTC. So, we report this case with the review of the literatures.
Diagnosis ; Mass Screening ; Multiple Endocrine Neoplasia ; Thyroid Gland* ; Thyroid Neoplasms*

This is a case report of a 51-year-old female diagnosed with papillary microcarcinoma of the thyroid gland after undergoing total thyroidectomy. A 99mTc pertechnetate thyroid scan was done before radioiodine ablation therapy. It showed cervical neck lymph nodes taking up the radiotracer. Another scan after ablation therapy showed the same nodes taking up the therapeutic iodine131. The paper discusses using 99mTc pertechnetate to detect thyroid cancer metastases.
Human ; Female ; Middle Aged ; THYROID NEOPLASMS ; NEOPLASMS ; NEOPLASMS BY SITE ; ENDOCRINE GLAND NEOPLASMS

The tumor node metastasis (TNM) system, which was developed by the American Joint Committee on Cancer (AJCC), is the most practical cancer staging system available. The AJCC TNM staging has been modified periodically in response to newly acquired clinical information and data on prognosis. The seventh edition of this system was published in late 2009 and the manual is effective for cancers diagnosed during or after 2010. There are 9 new classifications, 6 major modifications, elimination of cMX (metastasis cannot be assessed clinically), and there is an introduction to anatomical stages and prognostic groupings. But, compared to the 6th edition, there are no remarkable changes regarding ampulla of Vater and pancreatic cancer, except that neuroendocrine tumors of the pancreas now is staged as a carcinoma.
Ampulla of Vater ; Endocrine Gland Neoplasms ; Joints ; Neoplasm Metastasis ; Neoplasm Staging ; Neuroendocrine Tumors ; Pancreas ; Pancreatic Neoplasms ; Prognosis

PURPOSE: Thyroid cancer is the most common endocrine cancer and its incidence has continuously increased in the last three decades all over the world. We aimed to evaluate the prognostic value of extranodal extension (ENE) of thyroid cancer. MATERIALS AND METHODS: We performed a systematic search of MEDLINE (from inception to June 2014) and EMBASE (from inception to June 2014) for English-language publication. The inclusion criteria were studies of thyroid cancer that reported the prognostic value of ENE in thyroid cancer. Reviews, abstracts, and editorial materials were excluded, and duplicate data were removed. Two authors performed the data extraction independently. RESULTS: 6 studies including 1830 patients were eligible for inclusion in the study. All patients included in the meta-analysis had papillary thyroid cancer (PTC). Recurrence-free survival was analyzed based on 3 studies. The pooled hazard ratio for recurrence was 2.01 [95% confidence interval (CI) 1.19–3.40, p=0.009]. Disease-specific survival was analyzed based on 3 studies with 973 patients. Patients of PTC with ENE showed 3.37-fold higher risk of death from the disease (95% CI 1.55–7.32, p=0.002). CONCLUSION: ENE should be considered to be a poor prognostic marker in thyroid cancer; such knowledge might improve the management of individual patients. This might facilitate the planning of appropriate ablation therapy and tailored patient follow-up from the beginning of treatment.
Endocrine Gland Neoplasms ; Follow-Up Studies ; Humans ; Incidence ; Lymph Nodes ; Prognosis ; Publications ; Recurrence ; Thyroid Gland* ; Thyroid Neoplasms*

Multiple endocrine neoplasia (MEN) is defined as a disorder with neoplasms in two or more different hormonal tissues in several members of a family. MEN1, or Wermer's syndrome, is inherited as an autosomal dominant trait. This syndrome is characterized by neoplasia of the parathyroid glands, enteropancreatic tumors, anterior pituitary adenomas, and other neuroendocrine tumors with variable penetrance. Inherited medullary thyroid carcinoma (MTC) consists of MEN2A, MEN2B, and familial medullary thyroid cancer (FMTC). The identification of hereditary MTC has been facilitated in recent years by direct analysis of germline RET proto-oncogene mutation.
Carcinoma, Medullary ; Humans ; Multiple Endocrine Neoplasia ; Multiple Endocrine Neoplasia Type 1 ; Multiple Endocrine Neoplasia Type 2a ; Multiple Endocrine Neoplasia Type 2b ; Neuroendocrine Tumors ; Parathyroid Glands ; Penetrance ; Pituitary Neoplasms ; Proto-Oncogenes ; Thyroid Gland ; Thyroid Neoplasms

PURPOSE: Germline mutation of the RET oncogene results in multiple endocrine neoplasia (MEN) types 2A and 2B and familial medullary thyroid cancer (FMTC). We reviewed the literature to determine the mutation patterns of the RET oncogene in Koreans with MEN-2A, 2B and FMTC. METHODS: We retrieved the relevant literature using the PubMed (http://www.pubmed.org/) and KoreaMed (http://www.koreamed.org/) databases concerning the RET germline mutations in Korea from 1998 to 2010. We evaluated the pedigree of the patients to exclude the same, repeated families. We collected all the data on the types of mutations and the clinical syndromes. RESULTS: There were 21 studies with a total of 25 families. In the patients with MEN-2A and FMTC, there were 14 mutations (56%) in codon 634, 6 mutations (24%) in codon 618, 2 mutations (8%) in codon 631 and one mutation (4%) in codon 768. In the patients with MEN-2B, there were 2 mutations (8%) in codon 918. D631Y is an extremely rare mutation, but two families with such a mutation existed in Korea. The frequency of codon 634 mutations in the patients with MEN-2A was relatively lower than that of the previously reports from western countries and the frequency of codon 618 mutations was relatively higher than that in the western countries. CONCLUSION: This study shows there are hot spots and genotype- phenotype correlations for the RET oncogene mutations in Koreans.
Codon ; Germ-Line Mutation* ; Humans ; Korea ; Multiple Endocrine Neoplasia ; Oncogenes* ; Pedigree ; Phenotype ; Thyroid Gland* ; Thyroid Neoplasms*

Multiple endocrine neoplasi~a type 3 is a rare, heritable or sporadic, multiple neoplastic disorder that is charracterized by thyroid medullary careinoma, pheochromocytoma, multiple mucosal neuroma, and marfanoid habitus. The most important disorder of the syndrome is mucosal neuroma that is an early diagnostic sign of multiple endocrine neoplasia type 3. Early diagnosis of MEN type 3 determines prognosis of the disease. We present a case of multiple endocrine neoplasia type 3 of the sporadic pattern in a 27-year-old man who had typical medullary thyroid carcinoma, mucosal neuroma, marfanoid habitus, and megacolon.
Adult ; Early Diagnosis ; Humans ; Male ; Megacolon ; Multiple Endocrine Neoplasia* ; Neuroma* ; Pheochromocytoma ; Prognosis ; Thyroid Gland ; Thyroid Neoplasms

Carney complex is an autosomal dominant disorder that occurs due to a mutation in PRKAR1A, which encodes protein kinase A. The clinical features are multiple endocrine gland neoplasms, skin tumors, pigmented skin lesions, myxomas, and schwannomas. In Carney complex, the cardiac myxoma is a common co-morbidity. It occurs in multiples, during young age, regardless of gender and cardiac chamber and is known to recur frequently. Therefore there are high risks of adhesion and massive bleeding due to repeated surgeries. Such surgical risks account for over 50% of disease-specific mortality of Carney complex patients. Here, we present anesthetic experiences of myxoma removal surgery in two patients with Carney complex.
Anesthesia ; Carney Complex ; Cyclic AMP-Dependent Protein Kinases ; Endocrine Gland Neoplasms ; Hemorrhage ; Humans ; Myxoma ; Neurilemmoma ; Skin